Lobular carcinoma In Situ
Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form in the milk glands (lobules) in the breast. LCIS isn't cancer. But being diagnosed with LCIS indicates that you have an increased risk of developing breast cancer. It begins when cells in a milk-producing gland of a breast develop genetic mutations that cause the cells to appear abnormal. The abnormal cells remain in the lobule and don't extend into, or invade, nearby breast tissue. LCIS is viewed as an uncommon condition, but we don’t know exactly how many people are affected. That’s because LCIS does not cause symptoms and usually does not show up on a mammogram. It tends to be diagnosed as a result of a biopsy performed on the breast for some other reason. It is usually diagnosed before menopause, most often between the ages of 40 and 50. Less than 10% of women diagnosed with LCIS have already gone through menopause. This is extremely uncommon in men. This is described as pleomorphic or if it has necrosis (areas of dead cells), in which case it might be more likely to grow quickly.
Related Conference of Lobular carcinoma In Situ
6th International Conference on Breast Pathology and Cancer Diagnosis
Lobular carcinoma In Situ Conference Speakers
Recommended Sessions
- Atypical hyperplasia
- Benign Breast conditions
- Breast Anatomy
- Breast Cancer
- Breast cancer and the Immune system
- Breast cancer control and prevention
- Breast cancer Genes
- Breast cancer in Men
- Breast diseases
- Breast Implants
- Breast microcalcifications
- Ductal carcinoma In Situ
- Lobular carcinoma In Situ
- Surgery for Breast cancer
- Survivorship of Breast cancer
Related Journals
Are you interested in
- Anatomical Pathology - Pathology 2025 (UK)
- Breast Pathology - Pathology 2025 (UK)
- Cancer Pathology - Pathology 2025 (UK)
- Cancer Pathology and Oncology Diagnostics - Pathology Congress-2026 (UAE)
- Cardiovascular Pathology - Pathology Congress-2026 (UAE)
- Clinical Pathology - Pathology 2025 (UK)
- Clinical Pathology and Laboratory Medicine - Pathology Congress-2026 (UAE)
- Cytopathology and Fine Needle Aspiration (FNA) - Pathology Congress-2026 (UAE)
- Cytopathology and Histopathology - Pathology 2025 (UK)
- Dermatopathology - Pathology 2025 (UK)
- Digital Pathology and Artificial Intelligence - Pathology Congress-2026 (UAE)
- Digital Pathology and e-Pathology - Pathology 2025 (UK)
- Environmental and Occupational Pathology - Pathology Congress-2026 (UAE)
- Ethics and Innovations in Pathology - Pathology Congress-2026 (UAE)
- Forensic Pathology and Medical Examinations - Pathology Congress-2026 (UAE)
- Gastrointestinal and Liver Pathology - Pathology 2025 (UK)
- Hematopathology - Pathology 2025 (UK)
- Hematopathology and Blood Disorders - Pathology Congress-2026 (UAE)
- Histopathology and Tissue Engineering - Pathology Congress-2026 (UAE)
- Immunopathology and Autoimmune Diseases - Pathology Congress-2026 (UAE)
- Infectious Disease Pathology - Pathology Congress-2026 (UAE)
- Liver and Gastrointestinal Pathology - Pathology Congress-2026 (UAE)
- Microbial Pathology - Pathology 2025 (UK)
- Molecular Pathology - Pathology 2025 (UK)
- Molecular Pathology and Genomics - Pathology Congress-2026 (UAE)
- Neuropathology and Neurodegenerative Disorders - Pathology Congress-2026 (UAE)
- Oral and Maxillofacial Pathology - Pathology 2025 (UK)
- Pathology Informatics and Data Management - Pathology Congress-2026 (UAE)
- Pediatric Pathology - Pathology Congress-2026 (UAE)
- Renal Pathology - Pathology 2025 (UK)
- Renal Pathology - Pathology Congress-2026 (UAE)
- Surgical Pathology - Pathology 2025 (UK)
- Translational Pathology and Biomarkers - Pathology Congress-2026 (UAE)
- Veterinary Pathology - Pathology 2025 (UK)
- Veterinary Pathology - Pathology Congress-2026 (UAE)